Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06807281 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
Secondary endpoints: details revised at 8 of 17 entries
Study description revised
MinorTrial sites expanded: 38 → 41 locationsv17
MinorStudy sites: 37 to 38v16
MinorTrial sites expanded: 31 → 37 locationsv15
MinorTrial sites expanded: 26 → 31 locationsv14
MinorStudy sites: 18 to 26v13
NotableTrial status: Not Yet Recruiting to Recruiting
Study sites: 13 to 18
v12
MinorStudy sites: 7 to 13v11
MinorStudy sites: 4 to 7v10
MinorStudy sites: 2 to 4
Start date: Dec 11, 2025 to Dec 2, 2025
v9
MinorRe-verified, no change to tracked fieldsv8
NotableStart date: Nov 3, 2025 to Dec 11, 2025v7
MinorStudy sites: 0 to 2v6
Minor2 versionsRe-verified since May 12, 2025, no change to tracked fieldsv4-v5
NotablePrimary endpoints: 2 to 1
Secondary endpoints: 15 to 17
v3
MinorPrimary and study completion dates: Jan 17, 2032 to Feb 22, 2032v2
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This 24-month study will assess the long-term safety and efficacy of liquid abrocitinib oral suspension with or without topical medications in children 2 years of age or older with moderate-to-severe atopic dermatitis. The study will enroll two groups: participants who have completed other abrocitinib studies and participants who have never participated in abrocitinib studies.